You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Motor neurone disease

Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease

  • Technology appraisal guidance
  • Reference number: TA20
  • Published:  23 January 2001
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence
  • 5 Implications for the NHS
  • 6 Recommendations for research
  • 7 Implementation
  • 8 Clinical audit advice
  • 9 Appraisal committee members
  • 10 Sources of evidence

6 Recommendations for research

6.1

Further trials of riluzole are required to examine the relative effectiveness of differing dosing regimens.

6.2

Methods for the early diagnosis of MND require development as they may enable earlier treatment and enhanced clinical outcomes.


Next page 7 Implementation Previous page 5 Implications for the NHS
Back to top